AVX70371

Phase 1Biologic

AAstriVax Therapeutics

AVX70371 is one of 18 biologic programs targeting Chronic Hepatitis B Virus Infection. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Hepatitis B Virus InfectionActive, not recruiting

Chronic Hepatitis B Virus InfectionPhase 1

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Chronic Hepatitis B Virus Infection

#DrugCompanyPhaseTrials

Emtriva

Hepsera

Virazole

CConrado Roberto Hoffmann Filho

Approved

—4

Celebrex

PPhiladelphia Eye Associates

Approved

—5

Versed

CConrado Roberto Hoffmann Filho

Approved

—6

Alinia

RRomark Laboratories L.C.

Approved

—7

Cerubidine

HHikma Pharmaceuticals LLC

Bepirovirsen

1 9

PEG-IFNα

Gilead

Phase 2

2 10

VIR-3434

VVir Biotechnology, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis B Virus Infection1 trial

A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults

Active, not recruiting·AAstriVax Therapeutics·Phase 1·NCT06989788·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AVX70371. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AVX70371 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AVX70371. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstriVax Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: AAstriVax Therapeutics

AVX70371

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis B Virus Infection1 trial

References

Drug Info

Quick Facts

Related News